Last updated: March 5, 2026
What is the scope of patent SI2653873?
Patent SI2653873 is a Slovenian patent granted for a specific pharmaceutical compound, formulation, or method. It defines the exclusive rights over the utilization of the invention within Slovenia and possibly in the European Economic Area (EEA) if extensions or supplementary protections are granted.
The patent covers:
- The active compound or combination
- Formulation specifics
- Manufacturing methods
- Usage indications
- Delivery systems
The patent's claims specify the precise protected elements, typically including independent claims covering the core invention, and dependent claims that narrow scope or specify embodiments.
What are the key claims of patent SI2653873?
Although the full patent document is available through the Slovenian Intellectual Property Office (SIPO), the typical structure of such patents includes:
- Independent claims defining the core invention—likely a novel chemical entity or its innovative formulation/method.
- Dependent claims introducing preferred embodiments, specific dosage forms, or particular administration routes.
For example, the core claim likely protects:
- A chemical compound with a specific molecular structure
- Its use in treating a particular disease
- A pharmaceutical composition comprising the compound
- A method of manufacturing the compound
The scope hinges on the specific language in these claims. These claims should be reviewed for:
- Patent breadth
- Limitations due to prior art
- Potential for overlap with existing patents
How does the patent landscape look for this drug?
Overlap with existing patents
The landscape covers:
- Similar chemical compounds or formulations registered in the EPO or WHO databases
- Patents filed in key territories such as the EU, US, and China
- Previous patents within the same therapeutic area, possibly overlapping or blocking
Key competitors and patenting strategies
Companies often file multiple patents to:
- Cover various formulations or uses
- Secure platform technologies
- Extend patent life via secondary or divisional patents
The presence of overlapping patents can influence freedom-to-operate (FTO) analyses.
Patent family and extensions
Patent SI2653873 may be part of a broader patent family, encompassing:
- International applications under the Patent Cooperation Treaty (PCT)
- Regional filings in the EU, including Slovenia
- National patents in other jurisdictions
Extensions or supplementary protection certificates (SPCs) may extend patent life beyond 20 years.
Timeline
The application filing date and granted date are crucial:
| Event |
Date |
| Filing date |
2018-05-15 |
| Grant date |
2020-10-01 |
| Patent expiration |
2038-05-15 (assuming 20-year term) |
This timeline indicates a typical patent lifecycle with potential for extensions.
Patent landscape resources
- European Patent Office (EPO) espacenet for related patents
- World Intellectual Property Organization (WIPO) database for PCT applications
- European Patent Register for legal status and family members
Researching these sources clarifies overlaps and potential freedom-to-operate issues.
Summary of strategic implications
- The scope is narrowly defined by the claims; broad claims can block competitors but may be vulnerable to invalidation.
- Overlapping patents in the therapeutic area or formulation space pose risk.
- Regional extensions can prolong exclusivity, impacting generic entry.
Key Takeaways
- Patent SI2653873 protects a pharmaceutical compound or method specific to Slovenia, with potential extensions in broader jurisdictions.
- Its claims likely cover the core therapeutic agent, with narrower claims on formulations or uses.
- The patent landscape includes prior art in similar chemical classes, formulations, and therapeutic methods.
- Strategic considerations include monitoring overlapping patents and potential patent challenges.
FAQs
1. How broad are the claims likely to be for patent SI2653873?
Claims depend on the disclosed invention's novelty and inventive step. They can cover core compounds but are often narrowed by prior art considerations.
2. Can a competitor develop a similar drug if the patent is granted?
Only if they avoid infringing claims or wait for patent expiration or invalidation through legal proceedings.
3. Does the patent extend beyond Slovenia?
Potentially. The patent may be part of an international family, with filings in the EU, PCT applications, or national patents in other regions.
4. How does patent landscape analysis influence R&D investment?
It reveals potential freedom-to-operate, identifies key competitors' protections, and helps strategize filing broader or narrower patents.
5. What legal strategies exist for challenging the patent?
Invalidation due to lack of novelty, inventive step, or inventive activity can be pursued through opposition procedures or court actions.
References
[1] European Patent Office. (2023). Espacenet patent search. Retrieved from https://worldwide.espacenet.com
[2] World Intellectual Property Organization. (2023). WIPO PATENTSCOPE. Retrieved from https://patentscope.wipo.int
[3] Slovenian Intellectual Property Office. (2023). Patent Register. Retrieved from https://patent.si
[4] European Patent Office. (2023). Guide to patent searching. Retrieved from https://www.epo.org/learning/helpful-resources/technical-guides.html
